Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation

Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced that the first patient was dosed in a 6-month, multicenter, international Phase 2 clinical trial of a novel version of inhaled ciprofloxacin (ARD-3150) in 40 adult patients with non-cystic fibrosis bronchiectasis.

The randomized, double-blind, placebo-controlled trial will be conducted in Australia and New Zealand. Following a 14-day screening period, the patients will be treated once a day for 28 days with either the active drug, or placebo, followed by a 28-day off-treatment period. This on-off sequence will be repeated three times. The primary endpoint is defined as the mean change in Pseudomonas aeruginosa density in sputum (colony forming units – CFU - per gram) from baseline to day 28 of the active treatment group versus placebo. Safety and tolerability assessments of the treatment versus placebo group will be performed and secondary efficacy endpoints will include long-term microbiological responses, time to an exacerbation, severity of exacerbations, length of time to resolve exacerbations, and changes in spirometry and in quality-of-life measurements.

The study will explore whether the novel formulation ARD-3150, which has a different drug release profile than ARD-3100 (the formulation being studied under a U.S. IND in a separate 1-month dosing Phase 2b trial in a similar patient population), may have additional therapeutic benefits. The 6-month study will also generate valuable data on the long-term impact of once-daily inhaled ciprofloxacin in patients with severe bronchiectasis.

“Depending upon enrollment rates, the results of each of these trials are expected in the third quarter of 2010 and will provide us with an extensive data base of information, from which to select the optimum product and the most appropriate endpoints to test in Phase 3,” said Paul Bruinenberg, MD, Medical Director, Aradigm Corporation.


Aradigm Corporation


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Study suggests novel strategy to slow down evolution of antibiotic resistance